samedan logo
 
 
 
spacer
home > ebr > autumn 2002 > genentech and city of hope
PUBLICATIONS
European Biopharmaceutical Review

Genentech and City of Hope

In June 2002 the US trial jury's decisions in a contract dispute between City of Hope National Medical Center (COH) and Genentech, over royalties payable to COH under a research agreement, led to orders that Genentech pay COH US$500 million in damages (US$300 million compensatory and US$200 million punitive). This article discusses the dispute and raises points for consideration when drafting biotechnology and pharmaceutical research agreements. Under an agreement dated 5th August 1976, Genentech funded the research of Dr Riggs and Dr Itakura at COH regarding synthesis of DNA strands coding for somatostatin and insulin. The 1976 agreement contained provisions that Genentech would own patents that arose but pay royalties to COH on exploitation of the technology by Genentech or third party licensees. The Riggs/Itakura research is said to have led to over 100 patents held by Genentech worldwide and has yielded commercially successful technology, including synthetic insulin products (1). There were only three products for which COH provided synthetic DNA to Genentech: insulin, growth hormone and somatostatin. There is no commercial product associated with the third. Over the years, Genentech has paid COH royalties on the first two totalling approximately US$300 million.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Christopher Thornham, a Solicitor specialising in intellectual property law with Taylor Wessing

Christopher Thornham is a Solicitor specialising in intellectual property litigation, in particular patent and technology disputes. Christopher advises a variety of biotechnology and pharmaceutical companies.
He has a Natural Sciences degree from Cambridge University, UK and a Diploma in Intellectual Property Law and Practice from Bristol University, UK.

spacer
Christopher Thornham
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

KKR Invests in Biosynth Carbosynth to Accelerate Growth and Help Build Global Life Sciences Tools Platform

London and Staad, 1 November 2021 – KKR, a leading global investment firm, and Biosynth Carbosynth, a leading life sciences reagents and custom synthesis and manufacturing services company, announce today that KKR has agreed to acquire Biosynth Carbosynth from Armira and CEO Dr. Urs Spitz. Dr. Spitz and senior managers of the company will retain a significant ownership stake and will continue to lead the company as it embarks on its next chapter of growth. Financial details of the transaction, which is subject to customary regulatory approvals, were not disclosed.
More info >>

White Papers

What Your Clinical Study Design Reveals About Your Clinical Packaging Needs

PCI Pharma Services

As the cost and complexities of drug development increase, so do the challenges of global clinical trials. Today’s sponsors must be able to manage and coordinate multiple resources, processes, and locations with speed and accuracy to design effective and efficient clinical trials. Securing a stable supply chain to deal with the uncertainties of clinical trials is critical. One misstep can have a profound impact not only on the cost and time of your trial but also on its overall success.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement